Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jul 13:13:935803.
doi: 10.3389/fneur.2022.935803. eCollection 2022.

From the New Diagnostic Criteria to COVID-19 Pandemic Passing Through the Placebo Effect. What Have We Learned in the Management of Pediatric Migrane Over the Past 5 Years?

Laura Papetti  1 , Samuela Tarantino  1 , Fabiana Ursitti  1 , Romina Moavero  1   2 , Martina Checchi Proietti  1 , Giorgia Sforza  1 , Gabriele Monte  1 , Michela Ada Noris Ferilli  1 , Martina Balestri  3 , Federico Vigevano  3 , Massimiliano Valeriani  1   4
Affiliations
Review

From the New Diagnostic Criteria to COVID-19 Pandemic Passing Through the Placebo Effect. What Have We Learned in the Management of Pediatric Migrane Over the Past 5 Years?

Laura Papetti et al. Front Neurol. .

Abstract

In 2018, the Food and Drug Administration (FDA) approval of anti-calcitonin gene-related peptide (CGRP) therapies for the treatment of migraine represented a milestone for the management of the disease in adults. On the contrary, the novelties in the field of pediatric migraine are inserted in a different scenario and still concern: (1) diagnostic criteria of the international classification of headache disorders-3 (ICHD-3) that show numerous limits of applicability in the developmental age; (2) the release of the results of the Childhood and Adolescent Migraine Prevention (CHAMP) study that raised doubts about the usefulness of traditional drugs for the treatment of pediatric migraine; (3) the Coronavirus disease 2019 (COVID-19) pandemic has put the spotlight on the importance of managing the psychological factors associated with the disease. In this mini review we discuss the most relevant news in pediatric migraine over the last 5 years.

Keywords: children; diagnosis; headache; management; migraine; treatment.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

    1. Abu-Arafeh I, Gelfand AA. The childhood migraine syndrome. Nat Rev Neurol. (2021) 17:449–58. 10.1038/s41582-021-00497-6 - DOI - PubMed
    1. Papetti L, Salfa I, Battan B, Moavero R, Termine C, Bartoli B, et al. . Features of primary chronic headache in children and adolescents and validity of Ichd 3 criteria. Front Neurol. (2019) 10:92. 10.3389/fneur.2019.00092 - DOI - PMC - PubMed
    1. Gelfand AA. Pediatric and adolescent headache. Continuum. (2018) 24:1108–36. 10.1212/CON.0000000000000638 - DOI - PubMed
    1. Moavero R, Stornelli M, Papetti L, Ursitti F, Ferilli MAN, Balestri M, et al. . Medication overuse withdrawal in children and adolescents does not always improve headache: a cross-sectional study. Front Neurol. (2020) 11:823. 10.3389/fneur.2020.00823 - DOI - PMC - PubMed
    1. Papetti L, Ursitti F, Moavero R, Ferilli MAN, Sforza G, Tarantino S, et al. . Prophylactic treatment of pediatric migraine: is there anything new in the last decade? Front Neurol. (2019) 10:771. 10.3389/fneur.2019.00771 - DOI - PMC - PubMed